Today: 2 December 2025
Subscribe
Browse Category

Biotechnology News 17 November 2025 - 29 November 2025

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

Published: November 29, 2025 ImmunityBio, Inc. (NASDAQ: IBRX) has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of
29 November 2025
 ·  ·  ·  ·  · 
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

Hong Kong Exchanges & Clearing Limited (HKEX, stock code 388, ticker 0388.HK) traded slightly higher on Thursday, as investors digested a packed calendar of derivatives expiries, fresh sustainable‑finance headlines and the imminent launch of Hang Seng Biotech Index futures. The
27 November 2025
 ·  ·  ·  · 
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks
25 November 2025
 ·  ·  ·  ·  ·  · 
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November
21 November 2025
 ·  ·  ·  ·  · 
Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (NASDAQ: SHPH) surged over 25% in after‑hours and pre‑market trading on November 21, 2025 after an S‑1 filing, recent private placement and Nasdaq compliance update. Here’s what’s driving SHPH stock today. SHPH stock news today: why shares are
21 November 2025
 ·  ·  ·  ·  · 
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On
20 November 2025
 ·  ·  ·  ·  · 
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity
20 November 2025
 ·  ·  ·  ·  · 
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech
20 November 2025
 ·  ·  ·  ·  · 
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported
18 November 2025
 ·  ·  ·  · 
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1 The real catalyst comes
18 November 2025
 ·  ·  ·  ·  · 
Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

On November 17, 2025, Annovis Bio, Inc. (NYSE: ANVS) released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant subset of patients. Annovis
17 November 2025
 ·  ·  ·  · 
1 2 3 … 10
Go toTop